Literature DB >> 14640561

Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept.

Ranjita Banerjee1, Zakaria Rachid, James McNamee, Bertrand J Jean-Claude.   

Abstract

The synthesis of a novel acetoxymethyltriazene designed to be a prodrug of multiple inhibitors of the epidermal growth factor receptor (EGFR) and a methyldiazonium species is described. Studies with each of the expected metabolites demonstrated significant EGFR tyrosine kinase inhibitory activities and the released methyldiazonium was trapped with p-nitrobenzylpyridine. Their ability to damage genomic DNA in whole cells was demonstrated by using the single cell microelectrophoresis (comet) assay. The results suggest that this approach may well represent a novel drug combination strategy involving single molecules masking multiple bioactive agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14640561     DOI: 10.1021/jm030423m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain.

Authors:  Meaghan MacPhee; Zakaria Rachid; Margarita Todorova; Qiyu Qiu; Gina Belinsky; Bertrand J Jean-Claude
Journal:  Invest New Drugs       Date:  2010-04-29       Impact factor: 3.850

2.  Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.

Authors:  H L Watt; Z Rachid; B J Jean-Claude
Journal:  J Neurooncol       Date:  2010-05-14       Impact factor: 4.130

3.  The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries.

Authors:  Heather L Watt; Zakaria Rachid; Bertrand J Jean-Claude
Journal:  J Signal Transduct       Date:  2012-03-07

4.  Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting.

Authors:  Suman Rao; Anne-Laure Larroque-Lombard; Lisa Peyrard; Cédric Thauvin; Zakaria Rachid; Christopher Williams; Bertrand J Jean-Claude
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

5.  15N-, 13C- and ¹H-NMR Spectroscopy Characterization and Growth Inhibitory Potency of a Combi-Molecule Synthesized by Acetylation of an Unstable Monoalkyltriazene.

Authors:  Zhor Senhaji Mouhri; Elliot Goodfellow; Steven P Kelley; Robin S Stein; Robin D Rogers; Bertrand J Jean-Claude
Journal:  Molecules       Date:  2017-07-19       Impact factor: 4.411

6.  Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O6-methylguanine-DNA methyltransferase with a double arm hybrid molecule.

Authors:  Martin Rupp; Zhor Senhaji Mouhri; Christopher Williams; Bertrand J Jean-Claude
Journal:  Oncotarget       Date:  2018-10-12

7.  Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line.

Authors:  R Banerjee; Z Rachid; Q Qiu; J P McNamee; A M Tari; B J Jean-Claude
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.